Company intelligence / Profile preview
Spotlight Innovation
Iowa, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Spotlight Innovation's subsidiary Celtic Biotech is developing novel clinical trial-phase products for cancer and pain treatment. The lead program Crotoxin has advanced to Phase 2 for neoplasms, while Cobramine is in Phase 1 for chronic kidney disease and Phase 1 for colonic cancer. Crotamine is in preclinical stage for melanoma.
- Therapeutic areas
- OncologyNephrology
- Modalities
- Recombinant proteinSynthetic peptideGene therapy
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
FreeMind Group LLC (for grant and contract funding identification)
Beyond the preview
Go deeper on Spotlight Innovation.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Spotlight Innovation.